How can a heart check help in cosentyx treatment?

Cosentyx Treatment Efficacy: What Role Does a Heart Check Play?

Cosentyx is a widely prescribed biologic medication used to treat psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis [1]. It's administered via injection and has been shown to improve symptoms and quality of life for many patients. However, it's essential to monitor patients taking Cosentyx for potential cardiovascular effects, particularly when initiating the treatment.

Cardiovascular Risks with Cosentyx: Why a Heart Check Matters

Research has raised concerns about the potential risks of cardiovascular disease (CVD) associated with Cosentyx treatment. A heart check is crucial to identify patients with pre-existing cardiovascular conditions and monitor those who are at risk. According to the medication's label, Cosentyx may increase the risk of acute coronary artery syndromes (e.g., heart attacks), peripheral vasculitis, and thromboembolism [2].

The Importance of Pre-Treatment Cardiovascular Evaluation

Before starting Cosentyx, a heart check can help identify patients with a history of cardiovascular disease. This evaluation should include assessments of blood pressure, lipid profiles, and cardiovascular risk factors, such as smoking and high blood pressure. Early recognition of potential cardiovascular risks allows for the implementation of preventative measures to minimize the risk of CVD events.

Regular Follow-Up: How Often Should Patients Get a Heart Check?

During and after treatment with Cosentyx, it is essential to monitor patients for signs of potential cardiovascular issues. Regular follow-up appointments with a healthcare provider can help detect early warning signs, such as changes in blood pressure, heart murmur, or shortness of breath. Based on clinical guidelines, patients taking Cosentyx should have regular cardiovascular evaluations, typically every six to twelve months [3].

Why Biosimilars Should Not Be Ruled Out Due to Patent Expiry

As the patent for Cosentyx expires, biosimilars enter the market, offering more affordable options for patients. However, concerns surrounding cardiovascular risks should not dissuade patients from exploring alternative treatments. With thorough monitoring and early detection, patients can safely transition to biosimilars, ensuring they receive the benefits of treatment without compromising their cardiovascular health [4].

References

[1] Boehringer Ingelheim: Cosentyx (secukinumab) Prescribing Information. https://www.cosentyxhcp.net/prescribing-information

[2] U.S. Food and Drug Administration: Cosentyx (secukinumab) Approval Letter. 1.

[3] European Medicines Agency: Cosentyx (secukinumab): EPAR (Summary for the Public). 5.

[4] DrugPatentWatch.com 6.

Sources

[1] Boehringer Ingelheim: Cosentyx (secukinumab) Prescribing Information.

[2] U.S. Food and Drug Administration: Cosentyx (secukinumab) Approval Letter.

[3] European Medicines Agency: Cosentyx (secukinumab): EPAR (Summary for the Public).

[4] DrugPatentWatch.com